tirofiban and hirudin
tirofiban has been researched along with hirudin in 24 studies
Research
Studies (24)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (45.83) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Hetzer, R; Koster, A; Kuppe, H; Loebe, M; Mertzlufft, F | 1 |
| Bassand, JP | 1 |
| Caputo, RP; Esente, P; Giambartolomei, A; Reger, M; Simons, A; Wagner, S | 1 |
| Carrozza, JP; Cohen, DJ; Pinto, DS; Sperling, RT; Tu, TM | 1 |
| Cochran, K; DeMartini, TJ; Grassman, ED; Lewis, BE; Leya, F; O Brien, J; Steen, LH | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Allie, AA; Allie, DE; Allie, SE; Barker, EA; Chaisson, G; Fail, PS; Hebert, CJ; Keller, VA; Khan, MA; Khan, MH; Lirtzman, MD; McElderry, MW; Mitran, EV; Stagg, SJ; Vivekananthan, K; Walker, CM; Wyatt, CH | 1 |
| Bhatt, DL; Duffy, B | 1 |
| Braun, S; Dietrich, W; Eicken, A; Kostolny, M; Lange, R; Schreiber, C | 1 |
| Ligon, RW; Markwell, SJ; Mishkel, GJ; Moore, AL | 1 |
| Biondi-Zoccai, G; Bolognese, L; Briguori, C; Campo, G; Danzi, GB; Hamm, C; King, SB; Moliterno, DJ; Okmen, E; Saia, F; Tebaldi, M; ten Berg, J; Topol, EJ; Valgimigli, M; van't Hof, AW | 1 |
| Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G | 1 |
| Brazier, JE; Fox, KA; Schwenkglenks, M; Szucs, TD | 1 |
| Moliterno, DJ | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Heemskerk, JW; Lancé, MD; Lionikiene, AS; Mastenbroek, TG; Mutch, NJ; Swieringa, F; van der Meijden, PE; Whyte, CS | 1 |
| Cavender, MA; Faxon, DP | 1 |
| Chen, J; Chen, S; Guo, J; Han, Y; Jiang, D; Jiang, T; Jing, Q; Li, J; Li, Y; Liang, Z; Liu, H; Stone, GW; Su, X; Wang, Y; Xu, B; Yang, P; Zang, H; Zhao, X; Zheng, Y | 1 |
| He, Y; Jin, J; Li, J; Qian, D; Yu, S | 1 |
| Han, Y; Li, Y; Liang, Z; Liu, H; Ma, L; Stone, GW; Wang, D; Wang, J; Wang, S; Yang, L | 1 |
| Chen, SL; Chen, YD; Chen, YG; Cheng, XS; Ge, JB; Han, YL; Jiang, TM; Li, JL; Li, Y; Liang, ZY; Liu, HW; Liu, ML; Ma, LK; Ma, YT; Wang, G; Wang, HY; Xie, Q; Yang, BS; Zhao, X; Zheng, XQ | 1 |
| Bao, D; Chen, Y; Cong, H; Ding, S; Han, Y; Jia, S; Jing, Q; Li, J; Li, L; Li, Y; Liang, Z; Liu, B; Liu, H; Wang, H; Zhao, X | 1 |
| Anderson, JL; Bair, TL; Hackett, IS; Knowlton, KU; Lappé, DL; Le, VT; May, HT; Muhlestein, JB; Whisenant, B | 1 |
| Bärnthaler, T; Buschmann, E; Heinemann, A; Mahla, E; Prüller, F; Schuligoi, R; Toth, GG | 1 |
Reviews
7 review(s) available for tirofiban and hirudin
| Article | Year |
|---|---|
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Thrombocytopenia; Tirofiban; Tyrosine | 2003 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Clopidogrel; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Chemotherapy, Adjuvant; Hemorrhage; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Regression Analysis; Tirofiban; Tyrosine | 2010 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis.
Topics: Antithrombins; Cardiac Catheterization; Eptifibatide; Hirudins; Humans; Integrin alpha2; Myocardial Infarction; Peptide Fragments; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
Trials
6 trial(s) available for tirofiban and hirudin
| Article | Year |
|---|---|
Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recombinant Proteins; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Topics: Aged; Antithrombins; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine | 2015 |
The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Topics: Aged; Anticoagulants; Antithrombins; Chi-Square Distribution; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Emergency Treatment; Female; Hemorrhage; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Protective Factors; Recombinant Proteins; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cardiac Catheterization; China; Emergencies; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radial Artery; Recombinant Proteins; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Warfarin; Young Adult | 2017 |
Other Studies
11 other study(ies) available for tirofiban and hirudin
| Article | Year |
|---|---|
Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.
Topics: Cardiopulmonary Bypass; Drug Therapy, Combination; Female; Heart Valve Prosthesis Implantation; Heparin; Hirudins; Humans; Kidney Function Tests; Middle Aged; Mitral Valve; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Prosthesis Failure; Recombinant Proteins; Reoperation; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Topics: Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Insufficiency; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anticoagulants; Feasibility Studies; Female; Follow-Up Studies; Hirudins; Humans; Ischemia; Leg; Male; Myocardial Ischemia; Peptide Fragments; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Thrombin; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies.
Topics: Antibodies; Anticoagulants; Aprotinin; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Drug Therapy, Combination; Heart Valve Prosthesis Implantation; Hemostatics; Heparin; Hirudins; Humans; Male; Mitral Valve; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Factor 4; Recombinant Proteins; Reoperation; Thrombocytopenia; Tirofiban; Tyrosine; Ventricular Outflow Obstruction | 2006 |
Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Coronary Artery Disease; Costs and Cost Analysis; Drug Delivery Systems; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Length of Stay; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Models, Econometric; Myocardial Revascularization; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Quality-Adjusted Life Years; Recombinant Proteins; Survival Analysis; Tirofiban; Tyrosine; United Kingdom | 2011 |
Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.
Topics: Blood Platelets; Crotalid Venoms; Fibrin; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Flow Cytometry; Hemostatics; Hirudins; Lectins, C-Type; Microscopy, Confocal; Oligopeptides; Phosphatidylserines; Protein Binding; Rheology; Shear Strength; Thrombin; Thrombosis; Tirofiban; Tissue Plasminogen Activator; Tyrosine; Urokinase-Type Plasminogen Activator | 2015 |
Can BRIGHT restore the glow of bivalirudin?
Topics: Antithrombins; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine | 2015 |
[A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease].
Topics: Aged; China; Coronary Disease; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke; Tirofiban; Tyrosine | 2016 |
Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry).
Topics: Aged; Antithrombins; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Recombinant Proteins; Registries; Tirofiban; Treatment Outcome | 2019 |
Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study.
Topics: Aged; Aspirin; Calcium Signaling; Female; Fibrinogen; Hemorheology; Heparin; Hirudins; Humans; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tirofiban | 2020 |